List of works by Sagar Lonial

"A fortuitous combination of circumstances".

scientific article published in October 2013

14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells

scientific article published on 27 March 2007

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

scientific article (publication date: November 2016)

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci

scientific article published on September 2016

A Phase I/II Trial Combining High-Dose Melphalan and Autologous Transplant with Bortezomib for Multiple Myeloma: A Dose- and Schedule-Finding Study ⬇️

scientific article published on August 25, 2010

A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas

scientific article published on 3 January 2012

A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma

scientific article

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

scientific article

A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease

scientific article

A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma

scientific article

A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.

scientific article published on October 2007

A practical update on the use of bortezomib in the management of multiple myeloma

scientific article

A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma

scientific article published on 25 May 2012

A randomized clinical trial comparing granulocyte-colony-stimulating factor administration sites for mobilization of peripheral blood stem cells for patients with hematologic malignancies undergoing autologous stem cell transplantation

scientific article published on 18 February 2011

Academic, Foundation, and Industry Collaboration in Finding New Therapies

scientific article published on May 2017

Access to Children's Oncology Group and Pediatric Brain Tumor Consortium phase 1 clinical trials: Racial/ethnic dissimilarities in participation

scientific article published on 12 July 2016

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

scientific article published on 30 November 2006

Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients

scientific article published in June 2011

An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma

scientific article

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma

scientific article

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study

scientific article published on 18 August 2008

BCL2-BH4 antagonist BDA-366 suppresses human myeloma growth

scientific article published on 31 March 2016

Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma

scientific article published on February 2017

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

scientific article published in June 2005

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study

scientific article published on July 2010

Bortezomib-containing induction regimens in transplant-eligible myeloma patients: a meta-analysis of phase 3 randomized clinical trials

scientific article published on 4 September 2013

Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors

scientific article

Bortezomib-induced heat shock response protects multiple myeloma cells and is activated by heat shock factor 1 serine 326 phosphorylation

scientific article published on 26 July 2016

Breakthroughs in the management of multiple myeloma

scientific article

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

scientific article

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

scientific article published on 23 May 2016

Clinical uses of GM-CSF, a critical appraisal and update

scientific article published in March 2008

Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

scientific article published on 15 May 2010

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

scholarly article by Jonathan L Kaufman et al published 4 January 2019 in Blood Cancer Journal

Complete remission of multiple myeloma.

scientific article published on September 2007

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

scientific article

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

scientific article

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

scientific article published on 03 February 2011

Current advances in novel proteasome inhibitor-based approaches to the treatment of relapsed/refractory multiple myeloma.

scientific article

Current strategies for treatment of relapsed/refractory multiple myeloma

scientific article published on 29 January 2014

Daratumumab (anti-CD38) induces loss of CD38 on red blood cells

scientific article published on 3 April 2017

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

scientific article published on 6 January 2016

Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

scientific article

Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma

scientific article published on 21 November 2016

Deacetylase inhibitors: an advance in myeloma therapy?

scientific article

Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation

scientific article

Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells

scientific article

Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?

scientific article published on 5 May 2016

Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma

scientific article published on 31 May 2016

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

scientific article published on 2 June 2015

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

scientific article published on 16 November 2015

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma

scientific article

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth

scientific article

Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma

scientific article published on 23 October 2013

Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma

scientific article published on 17 March 2009

Emerging treatments in Castleman disease - a critical appraisal of siltuximab

scientific article

Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529.

scientific article published on 21 December 2007

Evaluating Risk Factors for Clostridium difficile Infection In Stem Cell Transplant Recipients: A National Study

scientific article

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models

Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation

scientific article published on January 2010

Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects

scientific article published in October 2003

FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway

scientific article published on September 2007

Facilitating T-cell immune reconstitution after haploidentical transplantation in adults

scientific article

Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformation

scientific article published on 17 February 2009

Frontline regimens for multiple myeloma patients.

scientific article published in May 2010

Future directions in immunomodulatory therapy

scientific article published on 11 December 2009

Gene integrated set profile analysis: a context-based approach for inferring biological endpoints

scientific article published on 29 January 2016

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

scientific article

Guidelines for the use and interpretation of assays for monitoring autophagy

scientific article

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

scientific article

HLA polymorphism and risk of multiple myeloma

scientific article published on 27 July 2016

HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers

scientific article

Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma

scientific article published on 14 December 2013

Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature

scientific article published on 12 May 2011

High-risk Multiple Myeloma: Definition and Management

scientific article

High-risk multiple myeloma: does it still exist?

scientific article published on 05 May 2011

High-risk myeloma: when to transplant-or not.

scientific article

Histone deacetylase inhibitors in multiple myeloma: rationale and evidence for their use in combination therapy

scientific article published on 17 June 2013

How I treat high-risk myeloma

scientific article published on 13 August 2015

How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma

scientific article published on 31 October 2016

Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee

scientific article

Immunomodulatory effects of human recombinant granulocyte-macrophage colony-stimulating factor (rhuGM-CSF): evidence of antitumour activity

scientific article

Improving induction therapy in multiple myeloma

scientific article published on July 2010

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

scientific article published on 23 July 2015

Induction therapy for newly diagnosed multiple myeloma

scientific article published on January 2013

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

scientific article

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers

scientific article published on 10 January 2011

Initial genome sequencing and analysis of multiple myeloma

scientific article

Insights Into the Appropriate Use of New Antimyeloma Therapies.

scientific article published in January 2017

Integrated analysis of whole-genome paired-end and mate-pair sequencing data for identifying genomic structural variations in multiple myeloma

scientific article

Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies

scientific article

Integration of Novel Agents into the Care of Patients with Multiple Myeloma

scientific article

Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma

scientific article

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation

scientific article published on 29 March 2011

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

scientific article

Is Maintenance Therapy for Everyone?

scientific article published on August 2016

Lack of health maintenance examinations and risk in myeloma patients

scientific article published on 27 April 2016

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

scholarly article by Joseph Mikhael et al published 29 August 2018 in Blood Cancer Journal

Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma

scientific article published on 3 July 2012

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

scientific article

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

scientific article

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

scientific article

MAX is an epigenetic sensor of 5-carboxylcytosine and is altered in multiple myeloma

scientific article

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

scientific article

Maintenance therapy in lymphoma

scientific article published on September 2007

Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma

scientific article

Melphalan or no melphalan: that is the question.

scientific article published in October 2010

Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling

scientific article

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens

scientific article published on 26 June 2009

Monoclonal Antibodies for the Treatment of Myeloma: Targeting SLAMF7 and CD38.

scientific article published on January 2016

Monoclonal antibodies in multiple myeloma: data from the 2015 ASH meeting

scientific article

Monoclonal antibodies in the treatment of multiple myeloma

scientific article published on 21 July 2011

Monoclonal gammopathy of undetermined significance: a consensus statement

scientific article

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

scientific article

Multiple myeloma presenting with advanced renal failure: a case report and new treatment options

scientific article published on February 2008

Multiple myeloma: novel approaches for relapsed disease.

scientific article published on December 2007

Multiple myeloma: the role of transplant and novel treatment strategies

scientific article published on April 2004

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

scientific article published on 11 December 2013

Myeloma Is Not a Single Disease

scientific article published on April 2016

New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma

scientific article published on 19 October 2016

New Targets and New Agents in High-Risk Multiple Myeloma

scientific article published on January 2016

New cancers after autotransplantations for multiple myeloma

scientific article

Novel Combination Treatments in Multiple Myeloma

scientific article

Novel combination approaches for myeloma

scientific article published in December 2015

Novel drug combinations for the management of relapsed/refractory multiple myeloma

scientific article published on September 2014

Novel treatment approaches for patients with multiple myeloma

scientific article

Novel treatment approaches for patients with relapsed and refractory multiple myeloma

scientific article

Older patients with myeloma derive similar benefit from autologous transplantation.

scientific article

Optimal dosing of melphalan as high-dose therapy before autologous hematopoietic stem cell transplantation in myeloma patients with solitary kidney: a case series

scientific article published on 15 November 2013

Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma

scientific article published on October 2006

Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.

scientific article published in April 2007

Outcomes of Allogeneic Stem Cell Transplant (allo-SCT) Recipients in the Era of Newer Antifungal Agents.

scientific article published on 29 April 2014

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

scientific article published on 14 October 2016

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma

scientific article

PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma

scientific article published on December 2007

Panobinostat for the treatment of multiple myeloma

scientific article published on 12 March 2012

Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes

scientific article

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

scientific article

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

scientific article

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

scientific article published on 07 June 2015

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy

scientific article

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

scientific article published on 11 October 2011

Perifosine synergistically enhances TRAIL-induced myeloma cell apoptosis via up-regulation of death receptors

scientific article

Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation

scientific article

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma

scientific article published on 20 March 2010

Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment

scientific article published on 29 November 2016

Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients

scientific article

Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma

scientific article

Phosphoglycerate Mutase 1 Coordinates Glycolysis and Biosynthesis to Promote Tumor Growth

scientific article

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study

scientific article published on 13 January 2014

Practical considerations for multiple myeloma: an overview of recent data and current options

scientific article

Predictors of survival outcomes in phase 1 relapsed or refractory multiple myeloma patients.

scientific article published on 6 November 2014

Presentation and risk stratification--improving prognosis for patients with multiple myeloma

scientific article published on May 2010

Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth

scientific article published on 9 January 2017

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma

scientific article

Proteasome inhibition: novel therapy for multiple myeloma

scientific article

Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation

scientific article

Racial differences in the incidence and outcomes for patients with hematological malignancies

scientific article published on May 2007

Rare myelomas: sometimes when you hear hooves, it's a zebra...

scientific article

Receiver operating characteristic curve analysis of circulating blood dendritic cell precursors and T cells predicts response to extracorporeal photopheresis in patients with chronic graft-versus-host disease

scientific article

Reconstructing immunity after allogeneic transplantation

scientific article published on January 2004

Regulation of alloimmune responses by dendritic cell subsets.

scientific article

Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib

scientific article published on 30 January 2013

Relapsed and refractory multiple myeloma: new therapeutic strategies

scientific article published on 23 July 2014

Results of a clinical phase I dose-escalation study of cytarabine in combination with fixed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma.

scientific article published on October 2006

Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma

scientific article published on 05 November 2018

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline

scientific article

Review of peripheral neuropathy in plasma cell disorders

scientific article published on June 2008

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

scientific article published on 3 August 2015

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

scientific article published on 4 January 2017

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

scientific article

Risky business in myeloma

scientific article

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

scientific article

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma

scientific article

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study

scientific article

Safety of proteasome inhibitors for treatment of multiple myeloma

scientific article published on 14 November 2016

Salvage second hematopoietic cell transplantation in myeloma

scientific article

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

scientific article

Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

scientific article published on 27 September 2012

Sequential or combination therapy for multiple myeloma

scientific article published on October 2012

Signal Transduction and Myeloma: New Targets, New Hope ⬇️

scientific article published on July 1, 2003

Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease

scientific article

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

scientific article published on 15 June 2009

Subcutaneous versus intravenous bortezomib: efficiency practice variables and patient preferences

scientific article published on September 2013

Supportive therapies in multiple myeloma

scientific article published on October 2009

Targeted therapy for haematological malignancies: clinical update from the American Society of Hematology, 2004.

scientific article

Temporal changes in plerixafor administration and hematopoietic stem cell mobilization efficacy: results of a prospective clinical trial in multiple myeloma

scientific article

Tetrameric Acetyl-CoA Acetyltransferase 1 Is Important for Tumor Growth

scientific article published on 9 November 2016

The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells.

scientific article published in March 2018

The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells

scientific article published on 13 September 2011

The Tao of myeloma

scientific article published on September 2014

The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway

scientific article

The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

scientific article published on 23 August 2005

The farnesyltransferase inhibitor R115777 up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer cells

scientific article published on May 2007

The future of drug development and therapy in myeloma

scientific article published on October 2013

The importance of complete response in outcomes in myeloma

scientific article

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

scientific article published on May 2007

Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomes ⬇️

scientific article published on September 15, 2010

Treatment of MM: Upcoming Novel Therapies

scientific article published on January 2016

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

scientific article published on 21 March 2016

Treatment of multiple myeloma: whence truth over belief?

scientific article published on April 2009

Treatment of relapsed and refractory myeloma

scientific article published on April 2009

Treatment options for relapsed and refractory multiple myeloma

scientific article published on March 2011

Treatment options for relapsed and refractory multiple myeloma

scientific article published on 02 April 2015

Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent

scientific article published on 8 September 2017

Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis

scientific article

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma

scientific article

Tyr phosphorylation of PDP1 toggles recruitment between ACAT1 and SIRT3 to regulate the pyruvate dehydrogenase complex

scientific article published on 30 January 2014

Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation

scientific article

Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth

scientific article

Tyrosine phosphorylation of lactate dehydrogenase A is important for NADH/NAD(+) redox homeostasis in cancer cells

scientific article published on 3 October 2011

Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism

scientific article

Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma

scientific article

Vinorelbine, paclitaxel, etoposide, cisplatin, and cytarabine (VTEPA) is an effective second salvage therapy for relapsed/refractory Hodgkin lymphoma

scientific article published on 02 October 2013

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

scientific article

When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response

scientific article published on 26 May 2015

Paulina is supported by:

About Paulina

Help